CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$48.92 USD
+0.63 (1.30%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $48.99 +0.07 (0.14%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$48.92 USD
+0.63 (1.30%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $48.99 +0.07 (0.14%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Zacks News
Earnings Growth & Price Strength Make CRISPR Therapeutics AG (CRSP) a Stock to Watch
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why
by Zacks Equity Research
Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.
How Are Genomics ETFs Responding to Q2 Earnings?
by Sweta Jaiswal, FRM
Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.
Bull of the Day: Vertex Pharmaceuticals (VRTX)
by Kevin Cook
Scientific innovation in the treatment of cystic fibrosis bolsters success and pipeline confidence
Vertex (VRTX) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Vertex's (VRTX) earnings and sales beat estimates in the second quarter of 2021. The company raises revenue guidance for the year.
CRISPR Therapeutics (CRSP) Q2 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) earnings and revenues beat estimates in the second quarter of 2021. Pipeline development in focus.
CRISPR Therapeutics AG (CRSP) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 125.30% and 32.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $119, marking a -0.63% move from the previous day.
CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look forward to the company's advancement with its lead gene-editing candidate CTX001.
CRISPR Therapeutics AG (CRSP) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics AG (CRSP) Stock Moves -0.67%: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $126.25 in the latest trading session, marking a -0.67% move from the prior day.
A Comprehensive Guide to Genomic ETFs
by Sweta Jaiswal, FRM
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
by Sweta Jaiswal, FRM
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals
Intellia (NTLA) Up on Positive Gene-Editing Drug Interim Data
by Zacks Equity Research
Intellia (NTLA) posts positive interim data from phase I study on lead genome-editing candidate NTLA-2001 being developed for treating transthyretin (ATTR) amyloidosis. Stock up.
3 Biotech Stocks Up on Intellia's CRISPR Therapy Study Data
by Zacks Equity Research
Intellia (NTLA) announces first-ever, promising clinical data on an in vivo CRISPR-based therapy. Stocks of CRSP, EDIT and BEAM rise on investor enthusiasm about their CRISPR-based candidates.
Stocks Roar Back on Infrastructure Expectations
by David Borun
The S&P 500 hits a fresh all-time high as Congress agrees to a bipartisan infrastructure bill.
Editas (EDIT) Begins Enrollment in Kids Arm of Gene Drug Study
by Zacks Equity Research
Editas (EDIT) starts enrollment of the first pediatric cohort in the phase I/II BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10). Stock up.
High-Growth Stocks Jump Back Into Investors' Favor
by Daniel Laboe
The short-term bottom for next-generation enterprises is in, and high multiple stocks are returning to investors' favor.
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $127.83, marking a +0.44% move from the previous day.
CRISPR (CRSP) Inks Deal for Gene Therapies in Neurological Diseases
by Zacks Equity Research
CRISPR Therapeutics (CRSP) signs a strategic collaboration with Capsida Biotherapeutics to develop/commercialize gene editing therapies for neurological diseases.
CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.
It Was a Very Quiet Week for US Equities, but a Significant Fed Meeting Looms
by David Borun
Stocks have found an equilibrium level for a slow Summer, yet this week all eyes are on the Fed for clues about interest rates.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $118.91, moving -0.24% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $114.74, moving -0.92% from the previous trading session.